Xeris Biopharma Holdings (XERS) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Xeris Biopharma Holdings published the results on November 5, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison.

• Xeris Biopharma reports in thousands; figures here are in millions.
• Xeris retired all of its 8.00% Convertible Senior Notes due 2028 on July 15, 2026. The exchange agreements for those notes produced a one-time non-cash charge of about $30.8 million in Q2 2026, and Xeris reported a net loss of $31.1 million for that quarter.

Source: Xeris Biopharma Q3 2026 results, November 5, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Xeris Biopharma Holdings splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Xeris Biopharma Holdings's Recorlev revenue was $71.5 million in Q3 2026, up 93% from $37.0 million in Q3 2025, 67% of total revenue.
• Xeris Biopharma Holdings's Gvoke revenue was $21.7 million in Q3 2026, down 14% from $25.2 million in Q3 2025, 20% of total revenue.
• Xeris Biopharma Holdings's Keveyis revenue was $13.0 million in Q3 2026, up 9% from $11.9 million in Q3 2025, 12% of total revenue.
• Xeris Biopharma Holdings's Royalty, contract and other revenue revenue was $1.0 million in Q3 2026, up 202% from $0.3 million in Q3 2025, under 1% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

The last line is from Chairman and CEO John Shannon. Xeris gives revenue guidance only.

In its Q3 2026 release, Xeris Biopharma Holdings said:

“Raises full-year 2026 total revenue guidance to $395 million to $405 million”

“Raises 2030 total revenue outlook to more than $1 billion, up from approximately $750 million”

“We now see Recorlev on a path to nearly $1 billion in annual net revenue three to four years sooner than previously expected.”

Source: Xeris Biopharma Q3 2026 release, Nov 5, 2026.

This is the company's own guidance as of Nov 5, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the XERS forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

Total revenue and diluted net income (loss) per common share, each as first reported in that quarter's release. Xeris announced expected Q4 and full-year 2025 revenue on January 8, 2026; the Q4 row uses the full release of March 2, 2026.

We do not hold a confirmed date for Xeris Biopharma Holdings's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 5, 2026

Xeris Biopharma's total revenue rose 44% to $107.2 million in Q3 2026 from $74.4 million a year earlier. Net product revenue was $106.3 million from three medicines Xeris sells in the United States only: Recorlev $71.5 million, Gvoke $21.7 million and Keveyis $13.0 million. Royalty, contract and other revenue was $1.0 million. (Xeris Biopharma Q3 2026 release, Nov 5, 2026; Xeris Biopharma Form 10-Q, Q3 2026, Nov 5, 2026)

Xeris's Recorlev, a cortisol synthesis inhibitor for endogenous Cushing's syndrome, grew from $37.0 million a year earlier. Its net revenue rose $34.6 million, or 93.5%: $27.5 million from higher volume driven by patient demand and $7.1 million from favorable net pricing. The CEO said the expanded commercial team delivered record referrals and new patient starts. (Xeris Biopharma Form 10-Q, Q3 2026, Nov 5, 2026; Xeris Biopharma Form 10-K, 2025, Mar 2, 2026; Xeris Biopharma Q3 2026 release, Nov 5, 2026)

Xeris's Gvoke, a ready-to-use liquid glucagon for severe hypoglycemia, fell 13.7%, with $4.2 million of unfavorable net pricing partly offset by $0.8 million of higher volume. Xeris said back-to-school prescription demand was stronger than in past years but was offset by a one-time ($4 million) gross-to-net adjustment. Keveyis, for primary periodic paralysis, rose 9.1% to $13.0 million on favorable net pricing. (Xeris Biopharma Form 10-Q, Q3 2026, Nov 5, 2026; Xeris Biopharma Q3 2026 release, Nov 5, 2026)

Xeris sells primarily to wholesalers or a specialty pharmacy that resell to retail pharmacies or patients, and records revenue net of rebates, chargebacks, discounts, copay assistance and product returns. Accrued trade discounts and rebates were $51.0 million at September 30, 2026, against $43.3 million at December 31, 2025. (Xeris Biopharma Form 10-Q, Q3 2026, Nov 5, 2026; Xeris Biopharma Q3 2026 release, Nov 5, 2026)

Xeris's net income was $11.3 million, or $0.06 per diluted share, in Q3 2026, against $0.6 million, or $0.00, a year earlier. Gross margin improved to 88% from 85% on product mix. Selling, general and administrative expenses rose $17.6 million, or 38%, to $64.1 million, mainly personnel costs to support the Recorlev expansion, and research and development rose 48% to $11.1 million to support XP-8121. (Xeris Biopharma Q3 2026 release, Nov 5, 2026)

Xeris reports adjusted EBITDA as its non-GAAP measure and no adjusted EPS. Adjusted EBITDA was $30.8 million, against $17.4 million, after adding back $10.8 million of share-based compensation, $6.5 million of interest expense and $3.0 million of depreciation and amortization. Interest expense was down from $7.3 million: on July 15, 2026 Xeris retired all of its 8.00% Convertible Senior Notes due 2028, eliminating about $34 million of debt and about $3 million of annual interest expense. (Xeris Biopharma Q3 2026 release, Nov 5, 2026)

Xeris's diluted weighted-average share count was 189,924,032, against 177,617,307, and 182,700,038 shares were outstanding at October 30, 2026. The 2028 notes were retired with a combination of cash and newly issued common stock. For the first nine months of 2026 Xeris had a net loss of $17.6 million, including a one-time non-cash charge of about $30.8 million in Q2 2026 from the exchange agreements for those notes. (Xeris Biopharma Q3 2026 release, Nov 5, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Xeris raised its full-year 2026 total revenue guidance to $395 million to $405 million with Q3 results, after $282.5 million in the first nine months. It also raised its 2030 total revenue outlook to more than $1 billion, from about $750 million, and said it now sees Recorlev on a path to nearly $1 billion of annual net revenue three to four years sooner than it previously expected. (Xeris Biopharma Q3 2026 release, Nov 5, 2026)

Xeris expects to start Cornerstone, the Phase 3 study of its once-weekly subcutaneous levothyroxine XP-8121, by year-end 2026, with topline data expected in late 2028 and potential approval and launch in 2030. The study is designed to enroll 500 adults and adolescents at more than 50 U.S. sites. (Xeris Biopharma Q3 2026 release, Nov 5, 2026)

A consensus figure is the average of the models published by the analysts who cover Xeris Biopharma Holdings, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Xeris Biopharma Holdings's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning XERS is on is XERS a buy or a sell?, what analysts expect next is on the XERS forecast, and what the company does is on the Xeris Biopharma Holdings (XERS) stock page.

Every number on this page can be traced to a document Xeris Biopharma Holdings published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.